Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Equipping cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …
Anti-ROR1 CAR-T cells: Architecture and performance
DA Osorio-Rodríguez, BA Camacho… - Frontiers in …, 2023 - frontiersin.org
The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a membrane receptor that
plays a key role in development. It is highly expressed during the embryonic stage and …
plays a key role in development. It is highly expressed during the embryonic stage and …
Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management
Simple Summary With around 15 kD molecular weight, VHHs are considered the smallest
antigen-binding fragments. Based on their unique properties, VHHs have broad application …
antigen-binding fragments. Based on their unique properties, VHHs have broad application …
Cutting-Edge Therapies for Lung Cancer
AS La'ah, SH Chiou - Cells, 2024 - mdpi.com
Lung cancer remains a formidable global health challenge that necessitates inventive
strategies to improve its therapeutic outcomes. The conventional treatments, including …
strategies to improve its therapeutic outcomes. The conventional treatments, including …
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
T Chen, J Deng, Y Zhang, B Liu, R Liu, Y Zhu, M Zhou… - Molecular Cancer, 2024 - Springer
Background Chimeric antigen receptor-T (CAR-T) cells therapy is one of the novel
immunotherapeutic approaches with significant clinical success. However, their applications …
immunotherapeutic approaches with significant clinical success. However, their applications …
Immunotherapeutic targeting of NG2/CSPG4 in solid organ cancers
H Zhang, Z Wu, D Hu, M Yan, J Sun, J Lai, L Bai - Vaccines, 2022 - mdpi.com
Neuro-glia antigen 2/chondroitin sulfate proteoglycan 4 (NG2/CSPG4, also called MCSP,
HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a large cell-surface antigen and an …
HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a large cell-surface antigen and an …
Cutting-edge CAR engineering: beyond T cells
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising
advanced therapies for the treatment of cancer, with unprecedented outcomes in …
advanced therapies for the treatment of cancer, with unprecedented outcomes in …
[HTML][HTML] Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
J Malhotra, A Huang, A Amini, P Lee - Cancers, 2024 - mdpi.com
Abstract Immunotherapy with PD-1/PD-L1 inhibitors is the standard method of care for the
treatment of newly diagnosed advanced or metastatic NSCLC, with or without …
treatment of newly diagnosed advanced or metastatic NSCLC, with or without …
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the
treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or …
treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or …